{
  "metadata": {
    "generated_at": "2025-10-02T06:33:55.704194",
    "dataset": {
      "name": "pharmacy_copilot_pharmacist_eval_v1",
      "description": "Gold pharmacist scenarios for LLM evaluation (enriched for deterministic scoring).",
      "version": "1.2.0"
    },
    "evaluation_time": 42.346434116363525,
    "judge_summary": {
      "mean_score": 80.76923076923077,
      "median_score": 85,
      "count": 13
    }
  },
  "aggregated_metrics": {
    "retrieval": {
      "recall_at_k": {
        "1": 0.6538461538461539,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "precision_at_k": {
        "1": 0.9230769230769231,
        "3": 0.5897435897435896,
        "5": 0.5897435897435896,
        "10": 0.5897435897435896,
        "20": 0.5897435897435896
      },
      "mean_reciprocal_rank": 0.9230769230769231,
      "average_precision": 0.9230769230769231,
      "ndcg_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "essential_recall_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "first_relevant_rank": 0.9230769230769231,
      "total_relevant": 19,
      "total_essential": 12
    },
    "qa": {
      "bleu_score": 0.02499692119753724,
      "rouge_1_f1": 0.30796081243751633,
      "rouge_2_f1": 0.13955809998460827,
      "rouge_l_f1": 0.21897741909766386,
      "semantic_similarity": 0.6053466223753415,
      "key_points_covered": 0.23351648351648355,
      "key_points_found": [],
      "key_points_missing": [],
      "answer_length": 33,
      "has_answer": true,
      "factual_accuracy": null,
      "helpfulness": null
    }
  },
  "detailed_results": [
    {
      "question_id": "q001",
      "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":810,\"volume_per_dose_mL\":10,\"frequency\":\"q12h\",\"max_daily_mg\":4000,\"rounding\":\"Round to nearest whole mL for volumes \u22655 mL\",\"calc_rule\":\"90 mg/kg/day \u00f7 2 doses = 45 mg/kg/dose \u00d7 18 kg = 810 mg/dose; volume = 810 mg \u00f7 (80 mg/mL)\",\"citations\":[\"lexi-amoxicillin-2018#dosage\",\"lexi-amoxicillin-2018#peds\"],\"notes\":\"High-dose amoxicillin regimen for AOM using 400 mg/5 mL suspension with practical mL rounding.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": 810,
          "volume_per_dose_mL": 10,
          "frequency": "q12h",
          "max_daily_mg": 4000,
          "rounding": "Round to nearest whole mL for volumes \u22655 mL",
          "calc_rule": "90 mg/kg/day \u00f7 2 doses = 45 mg/kg/dose \u00d7 18 kg = 810 mg/dose; volume = 810 mg \u00f7 (80 mg/mL)",
          "citations": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ],
          "notes": "High-dose amoxicillin regimen for AOM using 400 mg/5 mL suspension with practical mL rounding."
        },
        "failure_types": [
          "qa_incomplete"
        ]
      },
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h \u2192 810 mg per dose (\u224810.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The answer correctly calculates the dose, volume, frequency, and maximum daily dose, and cites appropriate chunks. However, the rounding rule is slightly misphrased but still acceptable."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-amoxicillin-2018#dosage",
          "lexi-amoxicillin-2018#peds"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Uses high-dose 80\u201390 mg/kg/day regimen",
        "Per-dose \u2248810 mg for 18 kg",
        "Max daily 4 g acknowledged",
        "No renal adjustment if normal function",
        "Cites pediatric dosage section"
      ]
    },
    {
      "question_id": "q002",
      "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":180,\"volume_per_dose_mL\":5.6,\"frequency\":\"q6h\",\"max_daily_mg\":900,\"rounding\":\"Round volume to nearest 0.1 mL\",\"calc_rule\":\"15 mg/kg/dose \u00d7 12 kg = 180 mg; Max daily = 75 mg/kg/day \u00d7 12 kg = 900 mg\",\"citations\":[\"lexi-acetaminophen-2018#peds-dosing\",\"lexi-acetaminophen-2018#max\"],\"notes\":\"Oral liquid acetaminophen dosed at 15 mg/kg/dose using 160 mg/5 mL concentration for fever management.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": 180,
          "volume_per_dose_mL": 5.6,
          "frequency": "q6h",
          "max_daily_mg": 900,
          "rounding": "Round volume to nearest 0.1 mL",
          "calc_rule": "15 mg/kg/dose \u00d7 12 kg = 180 mg; Max daily = 75 mg/kg/day \u00d7 12 kg = 900 mg",
          "citations": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ],
          "notes": "Oral liquid acetaminophen dosed at 15 mg/kg/dose using 160 mg/5 mL concentration for fever management."
        },
        "failure_types": [
          "qa_incomplete"
        ]
      },
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10\u201315 mg/kg q4\u20136h) \u2192 180 mg per dose \u22485.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and \u22644 g absolute.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The answer correctly calculates the dose and volume, cites appropriate chunks, and adheres to the maximum daily dose. All clinically substantive fields are supported."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#rectal",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-acetaminophen-2018#max",
          "lexi-acetaminophen-2018#peds-dosing"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Per-dose 15 mg/kg used",
        "q4\u20136h acceptable; target q6h in calc",
        "Volume \u22485.625 mL from 32 mg/mL",
        "Daily max 75 mg/kg/day and \u22644 g",
        "Pediatric dosing section cited"
      ]
    },
    {
      "question_id": "q003",
      "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":120,\"volume_per_dose_mL\":6.0,\"frequency\":\"q6-8h\",\"max_daily_mg\":480,\"rounding\":\"Round to nearest 0.5 mL\",\"calc_rule\":\"10 mg/kg/dose \u00d7 12 kg = 120 mg; max 40 mg/kg/day \u00d7 12 kg = 480 mg; volume = 120 mg \u00f7 (100 mg/5 mL)\",\"citations\":[\"lexi-ibuprofen-2018#peds-dosing\",\"lexi-ibuprofen-2018#max\"],\"notes\":\"Weight-based ibuprofen suspension dosing with caution in dehydration or renal risk.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": 120,
          "volume_per_dose_mL": 6.0,
          "frequency": "q6-8h",
          "max_daily_mg": 480,
          "rounding": "Round to nearest 0.5 mL",
          "calc_rule": "10 mg/kg/dose \u00d7 12 kg = 120 mg; max 40 mg/kg/day \u00d7 12 kg = 480 mg; volume = 120 mg \u00f7 (100 mg/5 mL)",
          "citations": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ],
          "notes": "Weight-based ibuprofen suspension dosing with caution in dehydration or renal risk."
        },
        "failure_types": [
          "qa_incomplete"
        ]
      },
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6\u20138h \u2192 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "judge_assessment": {
        "score": 80,
        "verdict": "manual_review",
        "rationale": "The answer correctly provides the dose, volume, frequency, and maximum daily dose, but the rounding rule is not supported by the evidence. The notes mention caution in dehydration or renal risk, which is acceptable, but the rounding rule is not aligned with the gold reference."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-ibuprofen-2018#max",
          "lexi-ibuprofen-2018#peds-dosing"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "10 mg/kg per dose",
        "q6\u20138h frequency",
        "120 mg per dose for 12 kg",
        "6 mL at 20 mg/mL",
        "Contraindication: <6 months; caution renal/dehydration"
      ]
    },
    {
      "question_id": "q004",
      "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":2.5,\"volume_per_dose_mL\":null,\"frequency\":\"q12h\",\"max_daily_mg\":5,\"rounding\":\"No rounding needed for fixed-dose tablet\",\"calc_rule\":\"Meets 2 of 3 criteria for dose reduction: weight \u226460kg (58kg) and SCr \u22651.5mg/dL (1.6mg/dL)\",\"citations\":[\"lexi-apixaban-2018#dosing-nvaf\",\"lexi-apixaban-2018#ddi\"],\"notes\":\"Reduced dose of 2.5mg BID indicated due to meeting 2 of 3 risk criteria, with tablet formulation not requiring volume measurement.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": 2.5,
          "volume_per_dose_mL": null,
          "frequency": "q12h",
          "max_daily_mg": 5,
          "rounding": "No rounding needed for fixed-dose tablet",
          "calc_rule": "Meets 2 of 3 criteria for dose reduction: weight \u226460kg (58kg) and SCr \u22651.5mg/dL (1.6mg/dL)",
          "citations": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ],
          "notes": "Reduced dose of 2.5mg BID indicated due to meeting 2 of 3 risk criteria, with tablet formulation not requiring volume measurement."
        },
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ]
      },
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age \u226580, weight \u226460 kg, SCr \u22651.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The answer correctly identifies the dose of apixaban as 2.5 mg BID based on the criteria met, cites appropriate chunks for support, and includes necessary interaction warnings. All clinically substantive fields are supported."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-apixaban-2018#vte",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-apixaban-2018#ddi",
          "lexi-apixaban-2018#dosing-nvaf"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Final dose 2.5 mg BID",
        "Interaction caveat: strong CYP3A4/P-gp",
        "Hepatic impairment caution"
      ]
    },
    {
      "question_id": "q005",
      "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":85,\"volume_per_dose_mL\":0.85,\"frequency\":\"q12h\",\"max_daily_mg\":170,\"rounding\":\"Round to nearest 0.1 mL\",\"calc_rule\":\"1 mg/kg \u00d7 85 kg = 85 mg per dose\",\"citations\":[\"lexi-enoxaparin-2018#dosing\"],\"notes\":\"Preferred regimen is 1 mg/kg q12h for acute DVT treatment with normal renal function, with each 100 mg/mL dose given subcutaneously.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": 85,
          "volume_per_dose_mL": 0.85,
          "frequency": "q12h",
          "max_daily_mg": 170,
          "rounding": "Round to nearest 0.1 mL",
          "calc_rule": "1 mg/kg \u00d7 85 kg = 85 mg per dose",
          "citations": [
            "lexi-enoxaparin-2018#dosing"
          ],
          "notes": "Preferred regimen is 1 mg/kg q12h for acute DVT treatment with normal renal function, with each 100 mg/mL dose given subcutaneously."
        },
        "failure_types": [
          "qa_incomplete"
        ]
      },
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h \u2192 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The answer correctly provides the enoxaparin dose of 85 mg per dose, frequency of q12h, and cites an allowed chunk. It also includes the renal adjustment information, fulfilling the requirements."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-enoxaparin-2018#dosing",
          "lexi-enoxaparin-2018#renal"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Alternative 1.5 mg/kg q24h",
        "Renal adjustment for CrCl <30"
      ]
    },
    {
      "question_id": "q006",
      "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m\u00b2. Can we use metformin?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"N/A\",\"max_daily_mg\":null,\"rounding\":\"N/A\",\"calc_rule\":\"Contraindicated if eGFR <30 mL/min/1.73m\u00b2; patient eGFR 28 is below threshold\",\"citations\":[\"lexi-metformin-2018#renal\"],\"notes\":\"Metformin is contraindicated at this eGFR of 28 mL/min/1.73m\u00b2 due to safety concerns\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "N/A",
          "max_daily_mg": null,
          "rounding": "N/A",
          "calc_rule": "Contraindicated if eGFR <30 mL/min/1.73m\u00b2; patient eGFR 28 is below threshold",
          "citations": [
            "lexi-metformin-2018#renal"
          ],
          "notes": "Metformin is contraindicated at this eGFR of 28 mL/min/1.73m\u00b2 due to safety concerns"
        },
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete"
        ]
      },
      "expected_answer": "No\u2014contraindicated at eGFR <30. If 30\u201345, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "judge_assessment": {
        "score": 80,
        "verdict": "manual_review",
        "rationale": "The answer correctly identifies metformin as contraindicated at eGFR <30 and cites one allowed chunk. However, it lacks coverage for the recommendation to avoid initiation at eGFR 30\u201345 and does not mention the need to reduce dose and monitor if continuing, which is critical information."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-metformin-2018#old-crcl60",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-metformin-2018#contra",
          "lexi-metformin-2018#renal"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "30\u201345: avoid initiation; if continuing, reduce & monitor",
        "Hepatic impairment: avoid (lactic acidosis risk)"
      ]
    },
    {
      "question_id": "q007",
      "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
      "llm_response": {
        "raw_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"n/a\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"n/a\",\n  \"calc_rule\": \"Contraindicated if eGFR <30 mL/min\",\n  \"citations\": [\"lexi-nitrofurantoin-2018#renal\", \"lexi-nitrofurantoin-2018#contra\"],\n  \"notes\": \"Nitrofurantoin is contraindicated at eGFR 25 mL/min due to inadequate urinary concentrations and increased toxicity risk.\"\n}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "n/a",
          "max_daily_mg": null,
          "rounding": "n/a",
          "calc_rule": "Contraindicated if eGFR <30 mL/min",
          "citations": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ],
          "notes": "Nitrofurantoin is contraindicated at eGFR 25 mL/min due to inadequate urinary concentrations and increased toxicity risk."
        },
        "failure_types": [
          "qa_incomplete"
        ]
      },
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The model correctly advises against nitrofurantoin use at eGFR 25 mL/min, citing appropriate evidence and rationale."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-nitrofurantoin-2018#contra",
          "lexi-nitrofurantoin-2018#renal"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Avoid if eGFR/CrCl <30",
        "Rationale: efficacy/toxicity",
        "List common contraindications where relevant"
      ]
    },
    {
      "question_id": "q008",
      "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"n/a\",\"max_daily_mg\":null,\"rounding\":\"n/a\",\"calc_rule\":\"DDI management rule: TMP-SMX increases warfarin effect via dual mechanisms\",\"citations\":[\"lexi-warfarin-2018#ddi-tmp-smx\"],\"notes\":\"TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut flora changes - avoid if possible or reduce warfarin dose with increased INR monitoring.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "n/a",
          "max_daily_mg": null,
          "rounding": "n/a",
          "calc_rule": "DDI management rule: TMP-SMX increases warfarin effect via dual mechanisms",
          "citations": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ],
          "notes": "TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut flora changes - avoid if possible or reduce warfarin dose with increased INR monitoring."
        },
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ]
      },
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "judge_assessment": {
        "score": 75,
        "verdict": "manual_review",
        "rationale": "The model correctly identifies the major interaction and mechanism but does not explicitly state the severity or action in the expected format. It cites the correct chunk but lacks clarity in the action recommendation."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-warfarin-2018#ddi-tmp-smx"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Severity: major"
      ]
    },
    {
      "question_id": "q009",
      "question": "Patient on atorvastatin needs clarithromycin. What\u2019s the risk and action?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"hold\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"hold atorvastatin during clarithromycin due to strong CYP3A4 inhibition\",\"citations\":[\"lexi-atorvastatin-2018#ddi-macrolides\"],\"notes\":\"Major interaction requiring atorvastatin hold or lowest dose with monitoring due to increased myopathy risk from CYP3A4 inhibition.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "hold",
          "max_daily_mg": null,
          "rounding": "not applicable",
          "calc_rule": "hold atorvastatin during clarithromycin due to strong CYP3A4 inhibition",
          "citations": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ],
          "notes": "Major interaction requiring atorvastatin hold or lowest dose with monitoring due to increased myopathy risk from CYP3A4 inhibition."
        },
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ]
      },
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "judge_assessment": {
        "score": 70,
        "verdict": "manual_review",
        "rationale": "The model correctly identifies the major interaction and cites the appropriate chunk, but the action is not clearly stated as 'avoid coadministration' and the frequency is inaccurately noted as 'hold' instead of specifying avoidance."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-atorvastatin-2018#ddi-macrolides"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Severity: major",
        "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
      ]
    },
    {
      "question_id": "q010",
      "question": "Starting linezolid in a patient on sertraline. Is this safe?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"N/A\",\"max_daily_mg\":null,\"rounding\":\"N/A\",\"calc_rule\":\"DDI assessment: linezolid MAOI activity + SSRI = contraindicated combination\",\"citations\":[\"lexi-linezolid-2018#ddi-ssri\"],\"notes\":\"Avoid concurrent use due to serotonin syndrome risk; if benefits outweigh risks, discontinue sertraline before starting linezolid and monitor closely.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "N/A",
          "max_daily_mg": null,
          "rounding": "N/A",
          "calc_rule": "DDI assessment: linezolid MAOI activity + SSRI = contraindicated combination",
          "citations": [
            "lexi-linezolid-2018#ddi-ssri"
          ],
          "notes": "Avoid concurrent use due to serotonin syndrome risk; if benefits outweigh risks, discontinue sertraline before starting linezolid and monitor closely."
        },
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ]
      },
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The model correctly identifies the major interaction and provides appropriate actions. It cites an allowed chunk and covers the key points, although it lacks specific numeric values for dose and frequency."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-linezolid-2018#ddi-ssri"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Mechanism: MAOI activity \u2192 \u2191serotonin",
        "Severity: major",
        "Action: avoid; or stop SSRI/close monitoring if unavoidable"
      ]
    },
    {
      "question_id": "q011",
      "question": "Patient on digoxin will start amiodarone. What\u2019s the interaction management?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"unchanged\",\"max_daily_mg\":null,\"rounding\":\"Reduce existing digoxin dose by 30-50%\",\"calc_rule\":\"Reduce existing digoxin dose by 30-50% due to P-glycoprotein inhibition by amiodarone\",\"citations\":[\"lexi-digoxin-2018#ddi-amio\"],\"notes\":\"Due to P-glycoprotein inhibition increasing digoxin exposure, reduce digoxin dose by 30-50% and monitor serum levels, renal function, and ECG when adding amiodarone.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "unchanged",
          "max_daily_mg": null,
          "rounding": "Reduce existing digoxin dose by 30-50%",
          "calc_rule": "Reduce existing digoxin dose by 30-50% due to P-glycoprotein inhibition by amiodarone",
          "citations": [
            "lexi-digoxin-2018#ddi-amio"
          ],
          "notes": "Due to P-glycoprotein inhibition increasing digoxin exposure, reduce digoxin dose by 30-50% and monitor serum levels, renal function, and ECG when adding amiodarone."
        },
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incomplete"
        ]
      },
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30\u201350% and monitor levels/ECG.",
      "judge_assessment": {
        "score": 80,
        "verdict": "manual_review",
        "rationale": "The model correctly identifies the major interaction and the need to reduce the digoxin dose by 30-50%, citing the appropriate chunk. However, it does not explicitly mention the mechanism of action (P-gp inhibition) in the main response, which is a critical aspect of the interaction management."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-digoxin-2018#ddi-amio"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Mechanism: P-gp inhibition \u2192 \u2191digoxin",
        "Severity: major"
      ]
    },
    {
      "question_id": "q012",
      "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"insufficient context - predates COVID therapies\",\"citations\":[\"kb-scope-2018#covid-absent\"],\"notes\":\"Knowledge base predates COVID-19 therapies including Paxlovid (nirmatrelvir/ritonavir); refer to current clinical guidance and pharmacist.\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "",
          "max_daily_mg": null,
          "rounding": "not applicable",
          "calc_rule": "insufficient context - predates COVID therapies",
          "citations": [
            "kb-scope-2018#covid-absent"
          ],
          "notes": "Knowledge base predates COVID-19 therapies including Paxlovid (nirmatrelvir/ritonavir); refer to current clinical guidance and pharmacist."
        },
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ]
      },
      "expected_answer": "ABSTAIN. Not in \u22642018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "judge_assessment": {
        "score": 70,
        "verdict": "manual_review",
        "rationale": "The model correctly abstains and advises consulting current guidance, but the evidence coverage for the explicit abstention is not fully supported by the allowed chunk."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "kb-scope-2018#covid-absent",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Explicit abstention",
        "Sets recency_risk = true",
        "Advises pharmacist/current guidance"
      ]
    },
    {
      "question_id": "q013",
      "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
      "llm_response": {
        "raw_answer": "{\"dose_per_dose_mg\":null,\"volume_per_dose_mL\":null,\"frequency\":\"\",\"max_daily_mg\":null,\"rounding\":\"not applicable\",\"calc_rule\":\"cannot determine from outdated 2014 guidelines\",\"citations\":[\"lexi-hypertension-2014#jnc8\"],\"notes\":\"Current first-line therapy cannot be determined as available context is from 2014 JNC8 guidelines which are outdated for current recommendations\"}",
        "parsed_answer": {
          "dose_per_dose_mg": null,
          "volume_per_dose_mL": null,
          "frequency": "",
          "max_daily_mg": null,
          "rounding": "not applicable",
          "calc_rule": "cannot determine from outdated 2014 guidelines",
          "citations": [
            "lexi-hypertension-2014#jnc8"
          ],
          "notes": "Current first-line therapy cannot be determined as available context is from 2014 JNC8 guidelines which are outdated for current recommendations"
        },
        "failure_types": [
          "qa_no_answer",
          "e2e_low_quality"
        ]
      },
      "expected_answer": "ABSTAIN if asked for \u2018current\u2019 guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "judge_assessment": {
        "score": 85,
        "verdict": "pass",
        "rationale": "The model correctly abstains from providing current guidelines, cites the outdated JNC8 (2014) reference, and sets recency risk. All key points are covered."
      },
      "retrieval_performance": {
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [
          "lexi-hypertension-2014#jnc8"
        ],
        "essential_chunks_missed": []
      },
      "key_points_missing": [
        "Explicit abstention for \u2018current\u2019 guideline ask",
        "Recognize JNC8 (2014) is outdated for \u2018current\u2019",
        "Sets recency_risk = true"
      ]
    }
  ]
}